ENTA
NASDAQEnanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc. (ENTA) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for ENTA, including 3 press releases and news items, 2 SEC filings and 1 leadership change. The most recent was published Nov 4, 2026.
ENTA rankings
Financial highlights
Full financials- Revenue, TTM
- $65.26M
- Revenue growth
- +0.7%
- Net income, TTM
- -$63.23M
- Net margin
- -96.9%
- Free cash flow, TTM
- -$36.94M
- Cash
- $33.42M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks19+400%
2026-05-172026-11-08
Mix890d
- Other5(63%)
- SEC Filings2(25%)
- Leadership1(13%)
Activity · 52 weeks8037 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PREnanta Pharmaceuticals to Participate in Upcoming Investor ConferencesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies Global Healthcare Conference in London: Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST 9th Annual Evercore Healthcare Conference: Fireside Chat on Wednesday, December 2, 2026, at 10:25 a.m. EST A live webcast of each event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta’s website at www.enanta.com. A rep
- SECSEC Form 8-K filed by Enanta Pharmaceuticals Inc.8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 8-K filed by Enanta Pharmaceuticals Inc.8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company LeadershipEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to serve as a Strategic Advisor for the remainder of 2027 to support a smooth and orderly transition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028569198/en/ The company also announces the appointment of Tara L. Kieffer, Ph.D. to the newly created role of
- PREnanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027. "We are excited to advance our zelicapavir program into a Phase 2b/3 study with
- PREnanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center in Washington, DC. Details of the presentation are as follows: Poster Title: Zelicapavir Decreases Time to Complete RSV Symptom Resolution, Hospitalization and Viral Load in a Global, Randomized, Double-Blinded, Placebo (PBO)-Contro
- PREnanta Pharmaceuticals to Participate in September Investor ConferencesEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September: Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET H.C. Wainwright 28th Annual Global Investment Conference: Fireside Chat on Wednesday, September 16, 2026 at 8:00 a.m. ET A live webcast of each event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta’s website at www.enanta.com. A replay of the webcasts wil
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.SCHEDULE 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)
- SECSEC Form 10-Q filed by Enanta Pharmaceuticals Inc.10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027 On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026 On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select an MRGPRX2 Development Candidate, in 2H 2026 Cash and Marketable Securities Totaling $211.5 Million at June 30, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund O
- INSIDERChief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 1,467 shares, decreasing direct ownership by 6% to 23,787 units (SEC Form 4) (withholding obligation)4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)
- SECSEC Form 8-K filed by Enanta Pharmaceuticals Inc.8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 424B5 filed by Enanta Pharmaceuticals Inc.424B5 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 8-K filed by Enanta Pharmaceuticals Inc.8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C VirusMAVIRET® (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis; Early Diagnosis and Treatment Help Reduce Transmission, Long-Term Liver-Related Complications, and Support HCV Elimination Efforts Glecaprevir, One of the Two Direct-Acting Antivirals in MAVIRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced t
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b
- PREnanta Pharmaceuticals to Present at the Jefferies Global Healthcare ConferenceEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be
- SECSEC Form S-8 filed by Enanta Pharmaceuticals Inc.S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECSEC Form 10-Q filed by Enanta Pharmaceuticals Inc.10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- SECEnanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)
- PREnanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV) On Track to File an IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate and to Select an MRGPRX2 Development Candidate, in 2H 2026 Cash and Marketable Securities Totaling $227 Million at March 31, 2026, as well as Continuing Retained Royalties, with Cash Runway Expected to Fund Operations into Fiscal 2029 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clin
- PREnanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an oral presentation highlighting zelicapavir and two posters with data on EPS-3903, a novel, potent and selective oral STAT6 inhibitor, at the American Thoracic Society (ATS) International Conference 2026 being held May 15-20, 2026 in Orlando, Florida. Details of the presentations are as follows: Title: Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial Abstract Number: 12336 Session C96:
- PREnanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaPhase 1 Study Will Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EDP-978 in Healthy Volunteers Topline Data Expected in Q4 2026 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the first participant has been dosed in a Phase 1 clinical trial of EDP-978, an oral, once-daily KIT inhibitor in development for urticaria and other mast cell-driven diseases. The Phase 1 single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodyn
ENTA FAQ
11 questionsWhat does Enanta Pharmaceuticals Inc. do?
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize...What is the latest news on ENTA?
In the last 30 days Quantisnow tracked 6 wire items for ENTA: 3 press releases and news items, 2 SEC filings and 1 leadership change. The most recent was published on November 4, 2026.What is ENTA revenue?
Enanta Pharmaceuticals Inc. (ENTA) reported $65.26M of revenue for the twelve months ended Jun 30, 2026. That is up 0.7% from the year before. Revenue for fiscal 2025 was $65.32M.Is ENTA profitable?
No. Enanta Pharmaceuticals Inc. reported a net loss of $63.23M for the twelve months ended Jun 30, 2026.How much cash and debt does ENTA have?
Enanta Pharmaceuticals Inc. reported $33.42M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does ENTA stock trade?
Enanta Pharmaceuticals Inc. (ENTA) is listed on NASDAQ.What sector and industry is ENTA in?
Enanta Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Enanta Pharmaceuticals Inc. go public?
Enanta Pharmaceuticals Inc. (ENTA) completed its IPO in 2013.What are analysts saying about ENTA?
Across the last 8 analyst actions on Enanta Pharmaceuticals Inc., there were 2 upgrades and 2 downgrades. The most recent action was from Rodman & Renshaw: Buy with a $20.00 price target on 2026-03-26. Recent price targets range from $14.00 to $62.00.What companies are similar to ENTA?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.), ABBV (AbbVie Inc.). Compare ENTA side-by-side with any of them on Quantisnow.How can I track ENTA on Quantisnow?
Quantisnow aggregates Enanta Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ENTA to receive live email and push alerts on every new disclosure.